Simplified composite disease activity measures in rheumatoid arthritis: Should they be used in standard care?

Clinical and Experimental Rheumatology

Volumn 26, Issue 2, 2008, Pages 358-366

  Bentley, Mary Jane ^a   Reed, George W ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Composite indices; Disease activity indices; Disease activity score (DAS); Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN;

AREA UNDER THE CURVE; CLINICAL ASSESSMENT TOOL; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EVALUATION; CONSTRUCT VALIDITY; CONTENT VALIDITY; CORRELATIONAL STUDY; CRITERION VALIDITY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; ERYTHROCYTE SEDIMENTATION RATE; FACE VALIDITY; FEASIBILITY STUDY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERMETHOD COMPARISON; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; REVIEW; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; VALIDITY;

ARTHRITIS, RHEUMATOID; HEALTH STATUS INDICATORS; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 43349099924     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2006; 65 (Suppl. 3): S2-15.
2. SMOLEN S, SOKKA T, PINCUS T, BREEDVELD FC: A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S209-10.
3. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
4. FELSON D T, ANDERSON J J, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
5. BOERS M, TUGWELL P, FELSON DT et al.: World health organization and international league of associations for rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 41: 86-9.
6. SMOLEN JS: The work of the EULAR standing committee on international clinical studies including therapeutic trials (ESCISIT). Br J Rheumatol 1992; 31: 219-20.
7. BOERS M, TUGWELL P: The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials. J Rheumatol 1993; 20: 568-74.
8. VAN DER HEIJDE DM, VAN'T HOF MA, VAN RIEL PL et al.: Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
9. VAN DER HEIJDE DM, VAN'T HOF MA, VAN RIEL PL, VAN DE PUTTE L: Disease activity score. Ann Rheum Dis 1992; 51: 140.
10. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
11. VAN GESTEL AM, PREVOO ML, VAN'T HOF MA, VAN RIJSWIJK MH, VAN DE PUTTE LB, VAN RIEL PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International league against rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
12. ALETAHA D, WARD MM, MACHOLD KP, NELL VP, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
13. WOLFE F, MICHAUD K, PINCUS T, FURST D, KEYSTONE E: The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005; 52: 3873-9.
14. SMOLEN JS: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003; 42: 244-57.
15. ALETAHA D: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-R806.
16. ALETAHA D, SMOLEN, JS: The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S100-S108.
17. PINCUS T: Advantages and limitations of quantitative measures to assess rheumatoid arthritis: Joint counts, radiographs, laboratory tests, and patient. Bull NYU Hosp Jt Dis 2006; 64: 32-9.
18. Boers M, Brooks P, Simon LS, Strand V, Tugwell P: OMERACT: An international initiative to improve outcome measurement in rheumatology. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S10-S13.
19. BOERS M, BROOKS P, STRAND CV, TUGWELL P: The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998; 25: 198-9.
20. LEEB BF, ANDEL I, SAUTNER J et al.: Disease activity measurement of rheumatoid arthritis: Comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum 2005; 53: 56-60.
21. VANDER CRUYSSEN B, VAN LOOY S, WYNS B et al.: DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: Validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005; 7: R1063-R1071.
22. RANGANATH VK, YOON J, ELASHOFF DA et al.: Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis 2007; 66: 1633-40
23. KHANNA D, OH M, FURST DE et al.: Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007; 57: 440-7.
24. GÜLFE A, GEBOREK P, SAXNET: Response criteria for rheumatoid arthritis in clinical practice: How useful are they? Ann Rheum Dis 2005; 64: 1186-89.
25. SMOLEN JS, VAN DER HEIJDE DM: Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant jnfliximab: Results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-10.
26. MIERAU M, SCHOELS M, GONDA G, FUCHS J, ALETAHA D, SMOLEN JS: Assessing remission in clinical practice. Rheumatology (Oxford) 2007; 46: 975-9.
27. SOUBRIER M, ZERKAK D, GOSSEC L, AYRAL X, ROUX C, DOUGADOS M: Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006; 33: 1243-6.
28. LEEB BF, ANDEL I, LEDER S, LEEB BA, RINTELEN B: The patient's perspective and rheumatoid arthritis disease activity indexes. Rheumatology 2005; 44: 360-5.
29. FRIES J F, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
30. LARSEN A: A radiological method for grading the severity of rheumatoid arthritis. Scand J Rheumatol 1975; 4: 225-33.
31. ALTMAN DG: Practical statistics for medical research. London: Chapman and Hall; 1991.
32. GOLDSMITH CH, BOERS M, BOMBARDIER C, TUGWELL P: Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT committee. J Rheumatol 1993; 20: 561-5.
33. VAN LEEUWEN MA, VAN DER HEIJDE DM, VAN RIJSWIJK MH et al.: Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21: 425-9.
34. ZWEIG M H, CAMPBELL G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77.
35. LANDEWE R, VAN DER HEIJDE DM, VAN DER LINDEN S, BOERS M: Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: A comparison with the original DAS remission. Ann Rheum Dis 2006; 65: 637-41.
36. VAN DER HEIJDE DM, JACOBS JW: The original "DAS" and the "DAS28" are not interchangeable: Comment on the articles by Prevoo et al. Arthritis Rheum 1998; 41: 942-5.
37. KAPRAL T, DERNOSCHNIG F, MACHOLD KP et al: Remission by composite scores in rheumatoid arthritis: Are ankles and feet important? Arthritis Res Ther 2007; 9: R72.
38. BROWN AK, QUINN MA, KARIM Z et al.: Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: Evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-73.
39. MAKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 1410-3.
40. BOMBARDIER C, TUGWELL P: A methodological framework to develop and select indices for clinical trials: Statistical and judgmental approaches. J Rheumatol 1982; 9: 753-7.
41. BOERS M: International consensus on which measures to use in rheumatoid arthritis clinical trials. Neth J Med 1993; 43: 55-8.